Gilead Sciences (GILD) Tops Q3 EPS by 94c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/8/2026

1. MRVL
2. ZS
3. PENG
4. NVDA
5. STZ
6. MSFT
7. SPY
8. SKYD
9. RCKT
10. IBM

Go back to Gilead Sciences (GILD) Tops Q3 EPS by 94c

Gilead Sciences Announces Third Quarter 2021 Financial Results

October 28, 2021 4:02 PM EDT

2 Million Patients Received Veklury (remdesivir) or Licensed Generic Remdesivir in the Third Quarter

Biktarvy Sales Increased 20% Year-Over-Year to Record $2.3 Billion

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the third quarter 2021.

This was a very strong third quarter with continued positive momentum for both our commercial performance and our pipeline progress, said Daniel ODay, Chairman and Chief Executive Officer, Gilead Sciences. Veklury is making a significant impact as the COVID-19 pandemic continues... More